Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19

Front Immunol. 2021 Feb 8:11:595342. doi: 10.3389/fimmu.2020.595342. eCollection 2020.

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory pathway. It is evident that nicotine, anisodamine and some herb medicine, activate the CAP and exert anti-inflammation action in vitro and in vivo. As the vagus nerve affects both inflammation and specific immune response, we propose that vagus nerve stimulation by invasive or non-invasive devices and acupuncture at ST36, PC6, or GV20, are also feasible approaches to activate the CAP and control COVID-19. It is worth to investigate the efficacy and safety of the strategy in patients with COVID-19.

Keywords: cholinergic anti-inflammatory pathway; coronavirus disease 2019; cytokine storm; therapeutic strategy; vagus nerve stimulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acupuncture
  • Anti-Inflammatory Agents / pharmacology
  • COVID-19 / therapy*
  • Cytokine Release Syndrome / therapy*
  • Cytokines / blood
  • Drugs, Chinese Herbal / pharmacology
  • Humans
  • Inflammation / therapy
  • Neuroimmunomodulation / immunology*
  • Nicotine / pharmacology
  • SARS-CoV-2
  • Solanaceous Alkaloids / pharmacology
  • Vagus Nerve / immunology*
  • Vagus Nerve Stimulation / methods*

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Drugs, Chinese Herbal
  • Solanaceous Alkaloids
  • anisodamine
  • Nicotine